ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Association of Lipoprotein(a)-Associated Mortality and the Estimated Glomerular Filtration Rate Level in Patients Undergoing Coronary Angiography: A 51,500 Cohort Study

Huang, Zhidong; Yang, Yanfang; Lu, Jin; Liang, Jingjing; He, Yibo; Yu, Yaren; Huang, Haozhang; Li, Qiang; Wang, Bo; Li, Shanggang; Yan, Zelin; Xu, Danyuan; Liu, Yong; Chen, Kaihong; Huang, Zhigang; Ni, Jindong; Liu, Jin*; Chen, Liling*; Chen, Shiqun*佛山市第一人民医院; 广东省人民医院; 广东省心血管病研究所; 广东医学院; 南方医科大学; 1
Frontiers in Cardiovascular Medicine2021-11-17DOI: 10.3389/fcvm.2021.747120
3被引12阅读
引用收藏
分享

摘要

Background: High lipoprotein(a) is associated with poor prognosis in patients at high risk for cardiovascular disease. Renal function based on the estimated glomerular filtration rate (eGFR) is a potential risk factor for the change of lipoprotein(a). However, the regulatory effect of eGFR stratification on lipoprotein(a)-associated mortality has not been adequately addressed.Methods: 51,500 patients who underwent coronary angiography (CAG) or percutaneous coronary intervention (PCI) were included from the Cardiorenal ImprovemeNt (CIN) study (ClinicalTrials.gov NCT04407936). These patients were grouped according to lipoprotein(a) quartiles (Q1-Q4) stratified by eGFR categories (<60 and >= 60 mL/min/1.73m(2)). Cox regression models were used to estimate hazard ratios (HR) for mortality across combined eGFR and lipoprotein(a) categories.Results: The mean age of the study population was 62.3 +/- 10.6 years, 31.3% were female (n = 16,112). During a median follow-up of 5.0 years (interquartile range: 3.0-7.6 years), 13.0% (n = 6,695) of patients died. Compared with lipoprotein(a) Q1, lipoprotein(a) Q2-Q4 was associated with 10% increased adjusted risk of death in all patients (HR: 1.10 [95% CI: 1.03-1.17]), and was strongly associated with about 23% increased adjusted risk of death in patients with eGFR <60 mL/min/1.73m(2) (HR: 1.23 [95% CI: 1.08-1.39]), while such association was not significant in patients with eGFR >= 60 mL/min/1.73m(2) (HR: 1.05 [95% CI: 0.97-1.13]). P for interaction between lipoprotein(a) (Q1 vs. Q2-Q4) and eGFR (>= 60 vs. eGFR <60 mL/min/1.73m(2)) on all-cause mortality was 0.019.Conclusions: Elevated lipoprotein(a) was associated with increased risk of all-cause mortality and such an association was modified by the baseline eGFR in CAG patients. More attention should be paid to the patients with reduced eGFR and elevated lipoprotein(a), and the appropriate lipoprotein(a) intervention is required.

学科与关键词

关键词
lipoprotein(a)estimated glomerular filtration rateall-cause mortalitycoronary angiographyrenal function
相关
加载中…
  • Baseline Low-Density-Lipoprotein Cholesterol Modifies the Risk of All-Cause Death Associated With Elevated Lipoprotein(a) in Coronary Artery Disease Patients
    Yao, Younan; Liu, Jin; Wang, Bo; Zhou, Ziyou; Lu, Xiaozhao; Huang, Zhidong; Deng, Jingru; Yang, Yongquan; Tan, Ning; Chen, Shiqun*; Chen, Jiyan*; Liu, Yong*Frontiers in Cardiovascular Medicine, 2022, 8: 817442.被引 1
  • Coronary Artery Disease: Optimal Lipoprotein(a) for Survival-Lower Is Better? A Large Cohort With 43,647 Patients
    Liu, Jin; Liu, Liwei; Wang, Bo; Chen, Shiqun; Liu, Buyun; Liang, Jingjing; Huang, Haozhang; Li, Qiang; Lun, Zhubin; Ying, Ming; Chen, Guanzhong; Huang, Zhidong; Xu, Danyuan; Yan, Xiaoming; Zhu, Tingting; Tadesse, Girmaw Abebe; Tan, Ning; Chen, Jiyan; Liu, Yong*Frontiers in Cardiovascular Medicine, 2021, 8: 670859.被引 2
  • Association of high-sensitivity C-reactive protein and long-term mortality may differ from lipoprotein(a) levels among patients undergoing coronary angiography
    Guo, Z.; Lei, L.; Ying, M.; Wang, B.; Liu, J.; Liu, L.; He, Y.; Sun, G.; Chen, S.; Liu, B.; Chen, G.; Chen, J.; Liu, Y.European-Society-of-Cardiology (ESC) Congress, ELECTR NETWORK, 2020-08-29 To 2020.
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Cardiovascular Medicine
发表日期
2021-11-17
卷期
第 8 卷
页码
747120
DOI
10.3389/fcvm.2021.747120
期刊收录
NSL
期刊等级
3区
成果收录
SCIE
资助标注
Fujian Province Natural Science Foundation [2019J01617]; Beijing Lisheng Cardiovascular Health Foundation [LHJJ20141751, DFJH201919]; Natural Science Foundation of Guangdong Province General Project [2020A1515010940]; Guangdong Provincial Key Laboratory of Coronary Heart Disease Prevention [2017B030314041]

作者

  • H

    Huang, Zhidong (第一作者)

  • Y

    Yang, Yanfang

    1 · fujian med univ

查看全部 19 位作者收起作者
  • L

    Lu, Jin

  • L

    Liang, Jingjing

    2 · southern med univ

  • H

    He, Yibo

    guangdong cardiovasc inst · guangdong prov peoples hosp

  • Y

    Yu, Yaren

    first peoples hosp foshan

  • H

    Huang, Haozhang

    guangdong cardiovasc inst · guangdong prov peoples hosp

  • L

    Li, Qiang

    guangdong cardiovasc inst · guangdong prov peoples hosp

  • W

    Wang, Bo

    guangdong cardiovasc inst · guangdong prov peoples hosp

  • L

    Li, Shanggang

    guangdong med univ

  • Y

    Yan, Zelin

    2 · southern med univ

  • X

    Xu, Danyuan

    guangdong cardiovasc inst · guangdong prov peoples hosp

  • L

    Liu, Yong

    guangdong cardiovasc inst · guangdong prov peoples hosp

  • C

    Chen, Kaihong

    1 · fujian med univ

  • H

    Huang, Zhigang

  • N

    Ni, Jindong

    guangdong med univ

  • L

    Liu, Jin (通讯)

    guangdong cardiovasc inst · guangdong prov peoples hosp

  • C

    Chen, Liling (通讯)

    1 · fujian med univ

  • C

    Chen, Shiqun (通讯)

    guangdong cardiovasc inst · guangdong prov peoples hosp

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417